Genetic Manipulation and Selection of Mouse Mesenchymal Stem Cells for Delivery of Therapeutic Factors In Vivo

Methods in Molecular Biology
Donald S Sakaguchi

Abstract

Bone marrow-derived mesenchymal stem cells (MSCs) hold great potential as an ex vivo cellular system for delivery of therapeutic proteins to the diseased or damaged central nervous system (CNS). This adult stem cell population has considerable translational potential for autologous transplantation due to lack of ethical concerns, accessibility, multipotent nature, and plasticity. Here we describe a methodology and outline a strategy using lentiviral vectors for producing lines of MSCs hypersecreting neurotrophic growth factors (e.g., brain-derived neurotrophic factor (BDNF) and/or glial cell line-derived neurotrophic factor (GDNF)) together with a reporter protein such as green fluorescent protein (GFP) that may be used for in vitro and in vivo neuroprotection bioassays. This approach provides exciting opportunities for basic research and proof-of-concept studies.

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Brain Injury & Trauma

brain injury after impact to the head is due to both immediate mechanical effects and delayed responses of neural tissues.